Serious adverse reactions including neurotoxicity (vertigo, tinnitus), ototoxicity (potential hearing loss, deafness, balance loss) and nephrotoxicity have occurred primarily in patients receiving systemic gentamicin therapy. However, systemic absorption following implantation of Collatamp G is unlikely to constitute a comparable risk.1
Rare / very rare incidents (maximum 1 incident by sales volume of 10,000 qty.) potentially associated with Collatamp G use include delayed/impaired wound healing, local infection / secretion, haematoma, seroma, elevated creatinine levels, sensitisation/hypersensitivity reactions, and thrombosis. Categories and ranges have been calculated based on `probability of occurrence’ estimates using the manufacturer’s risk management rating system. As a reference parameter, the probability of occurrence of an ´event per patient´ is used, which is based on product sales numbers.1
Adverse reactions should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or Search for MHRA Yellow Card in the Google Play or Apple App Store
Adverse reactions should also be reported to SERB SA via email at medinfo.uk1@serb.eu
References:
1. Instruction for use, May 2021
Disclaimer
You are leaving the Collatamp website.
This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. Serb declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, Serb is not responsible for any information or opinion contained in any third-party website.